We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PTBA:IDXPT Bukit Asam (Persero) Tbk Analysis

Data as of 2026-09-01 - not real-time

IDR 2,750.00

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

At IDR 2,750.00, PT Bukit Asam (Persero) Tbk shows no decisive moving-average alignment, leaving the trend neutral. Over a rolling month the price has gained 14.1%. Relative strength is 79.1 — overbought — and the MACD signal is bullish. The recent range runs from support at IDR 2,310.00 up to resistance at IDR 2,790.00.
On valuation the read is undervalued — earnings multiple of 9.5 versus a 21.6 sector average, below the peer group. Analyst price targets sit 10.6% above the current price. The 4.47% dividend yield looks stretched against payout coverage.
Risk comes out at 4 of a possible 10, a moderate reading. With 30-day volatility of 29.2%, a beta of -0.08 and a maximum drawdown of 28.6%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
The horizons line up on buy — conviction 6 out of 10.

Top Market Events

Langkah ini merupakan tindak lanjut atas ketentuan Undang-Undang Nomor 19 Tahun 2003 tentang Badan Usaha Milik Negara.KONTAN.CO.ID – JAKARTA. PT Bukit Asam Tbk PTBA telah mengantongi persetujuan Rencana Kerja dan Anggaran Biaya RKAB...PT Bukit Asam Tbk shares on the Indonesia Stock Exchange closed lower on 06/01/2026, with trading da

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 5/10

Key Factors

  • RSI at 79.1 signals overbought conditions
  • Trading above the 200-day average of 2564.10
  • MACD momentum is positive

Medium Term

1–3 years
Positive
Model confidence: 6/10

Key Factors

  • RSI at 79.1 signals overbought conditions
  • P/E of 9.5 versus sector average of 21.6
  • Dividend yield of 4.47% looks stretched against payout coverage

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • P/E of 9.5 versus sector average of 21.6
  • Dividend yield of 4.47% looks stretched against payout coverage
  • Analyst targets imply +10.6% versus the current price

Key Metrics & Analysis

Financial Health

Revenue Growth-0.30%
Profit Margin7.84%
P/E Ratio9.5
ROE14.41%
ROA5.27%
Debt/Equity11.49
P/B Ratio1.3
Op. Cash FlowIDR7108.0B
Free Cash FlowIDR488.1B
Industry P/E21.6

Technical Analysis

TrendNeutral
RSI79.1
SupportIDR 2,310.00
ResistanceIDR 2,790.00
MA 20IDR 2,416.50
MA 50IDR 2,393.80
MA 200IDR 2,564.10
MACDBullish
VolumeIncreasing
Fear & Greed Index94.55

Valuation

Fair ValueIDR 706.41
Target PriceIDR 3,042.14
Upside/Downside10.62%
GradeUndervalued
TypeValue
Dividend Yield4.47%

Risk Assessment

Beta-0.08
Volatility29.19%
Sector RiskHigh
Reg. RiskHigh
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.